Virulence attenuation during an influenza A/H5N1 pandemic

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 368, Issue 1614, 2013, Pages

  Boni, Maciej F ^a,b   Nguyen, Tran Dang ^a   de Jong, Menno D ^a,c   Rogier van Doorn, H ^a,b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

H5N1; Influenza; Mathematical modelling; Virulence evolution

Indexed keywords

DISEASE TRANSMISSION; EPIDEMIC; EPIDEMIOLOGY; EVOLUTIONARY THEORY; HEALTH RISK; INFLUENZA; MORTALITY; NUMERICAL MODEL; PATHOGEN; VACCINE; VIRULENCE;

ARTICLE; BIOLOGICAL MODEL; COMPUTER SIMULATION; EPIDEMIOLOGY; GENETICS; HUMAN; INFLUENZA; INFLUENZA VIRUS A H5N1; MOLECULAR EVOLUTION; PANDEMIC; PATHOGENICITY; PREVENTION; VIROLOGY; VIRULENCE;

COMPUTER SIMULATION; EPIDEMIOLOGY; EVOLUTION, MOLECULAR; GENETICS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, GENETIC; PANDEMICS; PATHOGENICITY; PREVENTION AND CONTROL; VIROLOGY; VIRULENCE;

CHINA; HONG KONG;

EID: 84873441318     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2012.0207     Document Type: Article

References (80)

1. Guan Y et al. 2004 H5N1 influenza: a protean pandemic threat. Proc. Natl Acad. Sci. USA 101, 8156-8161. (doi:10.1073/pnas.0402443101)
2. Li KS et al. 2004 Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern asia. Nature 430, 209-213. (doi:10.1038/ nature02746)
3. Herfst S et al. 2012 Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534-1541. (doi:10.1126/science.1213362)
4. Imai M et al. 2012 Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420-428.
5. Brouqui P et al. 2009 Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of infectious disease. Lancet Infect. Dis. 9, 301-311. (doi:10.1016/S1473-3099(09)70070-2)
6. Arinaminpathy N, McLean AR. 2008 Antiviral treatment for the control of pandemic influenza: some logistical constraints. J. R. Soc. Interface 5, 545-553. (doi:10.1098/rsif.2007.1152)
7. Nuno M, Chowell G, Gumel AB. 2007 Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and The Netherlands. J. R. Soc. Interface 4, 505-521. (doi:10.1098/rsif.2006.0186)
8. Regoes RR, Bonhoeffer S. 2006 Emergence of drugresistant influenza virus: population dynamical considerations. Science 312, 389-391. (doi:10.1126/science.1122947)
9. Oshitani H, Kamigaki T, Suzuki A. 2008 Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg. Infect. Dis. 14, 875. (doi:10.3201/eid1406.070839)
10. Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME. 2005 Containing pandemic influenza at the source. Science 309, 1083-1087. (doi:10.1126/science.1115717)
11. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS. 2005 Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437, 209-214. (doi:10.1038/nature04017)
12. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006 Strategies for mitigating an influenza pandemic. Nature 442, 448-452. (doi:10.1038/nature04795)
13. Perez Velasco R, Praditsitthikorn N, Wichmann K, Mohara A, Kotirum S, Tantivess S, Vallenas C, Harmanci H, Teerawattananon Y. 2012 Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics. PLoS ONE 7, e30333. (doi:10.1371/ journal.pone.0030333)
14. Adisasmito W et al. 2010 Effectiveness of antiviral treatment in human influenza a (H5N1) infections: analysis of a global patient registry. J. Infect. Dis. 202, 1154-1160. (doi:10.1086/656316)
15. Hernán MA, Lipsitch M. 2011 Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin. Infect. Dis. 53, 277-279. (doi:10.1093/cid/cir400)
16. Hsu J et al. 2012 Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann. Int. Med. 156, 512-524. (doi:10.1059/0003-4819-156-7-201204030-00411)
17. Tambyah PA et al. 2012 Safety and immunogenicity of two different doses of a vero cell-derived, whole virus clade 2 H5N1 (a/indonesia/05/2005) influenza vaccine. Vaccine 30, 329-335. (doi:10.1016/j. vaccine.2011.10.088)
18. Gillard P, Caplanusi A, Knuf M, Roman F, Walravens K, Moris P, Dramé M, Schwarz TF. 2012 An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Respir. Viruses 7, 55-65. (doi:10.1111/j. 1750-2659.2012.00349.x)
19. Bootsma MCJ, Ferguson NM. 2007 The effect of public health measures on the 1918 influenza pandemic in US cities. Proc. Natl Acad. Sci. USA 104, 7588-7593. (doi:10.1073/pnas.0611071104)
20. Hatchett RJ, Mecher CE, Lipsitch M. 2007 Public health interventions and epidemic intensity during the 1918 influenza pandemic. Proc. Natl Acad. Sci. USA 104, 7582-7587. (doi:10.1073/pnas.0610941104)
21. Caley P, Philp DJ, McCracken K. 2008 Quantifying social distancing arising from pandemic influenza. J. R. Soc. Interface 5, 631-639. (doi:10.1098/rsif.2007.1197)
22. Normile D. 2005 Pandemic skeptics warn against crying wolf. Science 310, 1112-1113. (doi:10.1126/ science.310.5751.1112)
23. Hatta M, Gao P, Halfmann P, Kawaoka Y. 2001 Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293, 1840-1842. (doi:10.1126/science.1062882)
24. Rudneva IA, Ilyushina NA, Timofeeva TA, Webster RG, Kaverin NV. 2005 Restoration of virulence of escape mutants of H5 and H9 influenza viruses by their readaptation to mice. J. Gen. Virol. 86, 2831-2838. (doi:10.1099/vir.0.81185-0)
25. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y. 2007 Growth of H5N1 influenza a viruses in the upper respiratory tracts of mice. PLoS Pathog. 3, e133. (doi:10.1371/ journal.ppat.0030133)
26. Hatta Y, Hershberger K, Shinya K, Proll SC, Dubielzig RR, Hatta M, Katze MG, Kawaoka Y, Suresh M. 2010 Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog. 6, e1001139. (doi:10.1371/journal. ppat.1001139)
27. Li J, Li Y, Hu Y, Chang G, Sun W, Yang Y, Kang X, Wu X, Zhu Q. 2011 PB1-mediated virulence attenuation of H5N1 influenza virus in mice is associated with PB2. J. Gen. Virol. 92, 1435-1444. (doi:10.1099/vir.0.030718-0)
28. Memoli MJ, Jagger BW, Dugan VG, Qi L, Jackson JP, Taubenberger JK. 2009 Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift. J. Infect. Dis. 200, 1232-1241. (doi:10.1086/605893)
29. Schrauwen EJAA, Herfst S, Chutinimitkul S, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Kuiken T, Fouchier RAM. 2011 Possible increased pathogenicity of pandemic (H1N1) 2009 influenza virus upon reassortment. Emerg. Infect. Dis. 17, 200-208. (doi:10.3201/eid1702.101268)
30. Suguitan AL, Matsuoka Y, Lau Y-F, Santos CP, Vogel L, Cheng LI, Orandle M, Subbarao K. 2012 The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) Avian influenza virus acts as a virulence factor in a Host-specific manner in mammals. J. Virol. 86, 2706-2714. (doi:10.1128/JVI.05546-11)
31. Taubenberger JK, Morens DM. 2006 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis. 12, 15-22.
32. WHO/GIP. 2012 Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003-2012. See http://www.who.int/ influenza/human_animal_interface/EN_GIP_20120706CumulativeNumberH5N1cases.pdf.
33. Palese P, Wang TT. 2012 H5N1 influenza viruses: facts, not fear. Proc. Natl Acad. Sci. USA 109, 2211-2213. (doi:10.1073/pnas.1121297109)
34. Wang TT, Parides MK, Palese P, 2012. Seroevidence for H5N1 influenza infections in humans: metaanalysis. Science 335, 1463. (doi:10.1126/science.1218888)
35. Osterholm MT, Kelley NS. 2012 H5N1 influenza virus seroepidemiological studies: the facts revisited. Proc. Natl Acad. Sci. USA 109, E1332. (doi:10.1073/ pnas.1203949109)
36. Van Kerkhove MD et al. 2012 Comment on 'seroevidence for H5N1 influenza infections in humans: meta-analysis'. Science 336, 1506. (doi:10.1126/science.1221434)
37. Palese P, Wang TT. 2012 Reply to Osterholm and Kelley: H5N1 in humans-the threat is not as bad as it may seem. Proc. Natl Acad. Sci. USA 109, E1333. (doi:10.1073/pnas.1204160109)
38. Wang TT, Palese P. 2012 Response to comment on seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 336, 1506. (doi:10.1126/science.1221633)
39. Antia R, Regoes RR, Koella JC, Bergstrom CT. 2003 The role of evolution in the emergence of infectious diseases. Nature 426, 658-661. (doi:10.1038/ nature02104)
40. Day T, André JB, Park A. 2006 The evolutionary emergence of pandemic influenza. Proc. R. Soc. B 273, 2945-2953. (doi:10.1098/rspb.2006.3638)
41. Levin S, Pimentel D. 1981 Selection of intermediate rates of increase in parasite-host systems. Am. Nat. 117, 308-315. (doi:10.1086/283708)
42. Anderson RM, May RM. 1982 Coevolution of hosts and parasites. Parasitology 85, 411-426. (doi:10.1017/S0031182000055360)
43. May RM, Anderson RM. 1983 Epidemiology and genetics in the coevolution of parasites and hosts. Proc. R. Soc. Lond. B 219, 281-313. (doi:10.1098/ rspb.1983.0075)
44. Frank SA. 1996 Models of parasite virulence. Q. Rev. Biol. 71, 37-78. (doi:10.1086/419267)
45. Galvani AP. 2003 Epidemiology meets evolutionary ecology. Trends Ecol. Evol. 18, 132-139. (doi:10.1016/S0169-5347(02)00050-2)
46. Day T. 2003 Virulence evolution and the timing of disease life-history events. Trends Ecol. Evol. 18, 113-118. (doi:10.1016/S0169-5347(02)00049-6)
47. Day T, Proulx SR. 2004 A general theory for the evolutionary dynamics of virulence. Am. Nat. 163, E40-E63. (doi:10.1086/382548)
48. Day T, Gandon S. 2006 Insights from Price's equation into evolutionary epidemiology. In Disease evolution: concepts, models, data analyses (eds Z Feng, U Dieckmann, S Levin), pp. 23-43. Providence, RI: American Mathematical Society.
49. Boni MF, Gog JR, Andreasen V, Feldman MW. 2006 Epidemic dynamics and antigenic evolution in a single season of influenza A. Proc. R. Soc. B 273, 1307-1316. (doi:10.1098/rspb.2006.3466)
50. Peiris JSM, de Jong MD, Guan Y. 2007 Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 20, 243-267. (doi:10.1128/ CMR.00037-06)
51. Hien TT. et al. 2004. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350, 1179-1188. (doi:10.1056/NEJMoa040419)
52. de Jong MD et al. 2005 Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352, 686-691. (doi:10.1056/NEJMoa044307)
53. Chotpitayasunondh T et al. 2005 Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 11, 201-209. (doi:10.3201/eid1102.041061)
54. Kandun IN et al. 2006 Three indonesian clusters of h5n1 virus infection in 2005. N. Engl. J. Med. 355, 2186-2194. (doi:10.1056/NEJMoa060930)
55. Oner AF et al. 2006. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N. Engl. J. Med. 355, 2179-2185. (doi:10.1056/NEJMoa060601)
56. Sedyaningsih ER et al. 2007 Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J. Infect. Dis. 196, 522-527. (doi:10.1086/519692)
57. Abdel-Ghafar AN et al. 2008 Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358, 261-273. (doi:10.1056/ NEJMra0707279)
58. Liem NT et al. 2009 Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin. Infect. Dis. 48, 1639-1646. (doi:10.1086/599031)
59. de Jong MD et al. 2006 Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203-1207. (doi:10.1038/nm1477)
60. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004 Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl Acad. Sci. USA 101, 4620. (doi:10.1073/pnas.0308001101)
61. Nicholls JM, Chan RWY, Russell RJ, Air GM, Peiris JSM. 2008 Evolving complexities of influenza virus and its receptors. Trends Microbiol. 16, 149-157. (doi:10.1016/j.tim.2008.01.008)
62. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. 2006 Avian flu: influenza virus receptors in the human airway. Nature 440, 435-436. (doi:10.1038/440435a)
63. Couceiro JNSS, Paulson JC, Baum LG. 1993 Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29, 155-165. (doi:10.1016/0168-1702(93)90056-S)
64. Thanh TT, van Doorn HR, de Jong MD. 2008 Human (H5N1) influenza: Current insights into pathogenesis. Intl. J. Biochem. Cell Biol. 40, 2671-2674. (doi:10.1016/j.biocel.2008.05.019)
65. Day T, Gandon S. 2007 Applying population-genetic models in theoretical evolutionary epidemiology. Ecol. Lett. 10, 876-988. (doi:10.1111/j.1461-0248.2007.01091.x)
66. Reperant LA, Kuiken T, Grenfell BT, Osterhaus ADME, Dobson AP. 2012 Linking influenza virus tissue tropism to population-level reproductive fitness. PLoS ONE 7, e43115. (doi:10.1371/journal.pone.0043115)
67. Reperant LA, Kuiken T, Osterhaus ADME. 2012. Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans. Vaccine 30, 4419-4434. (doi:10.1016/j.vaccine.2012.04.049)
68. Neumann G, Kawaoka Y. 2006 Host range restriction and pathogenicity in the context of influenza pandemic. Emerg. Infect. Dis. 12, 881-886. (doi:10.3201/eid1206.051336)
69. Killingley B et al. 2012. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. J. Infect. Dis. 205, 35-43. (doi:10.1093/infdis/jir701)
70. Lessler JT, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. 2009 Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect. Dis. 9, 291-300. (doi:10.1016/S1473-3099(09)70069-6)
71. Hien TT et al. 2010 Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis. PLoS Med. 7, e1000277. (doi:10.1371/journal. pmed.1000277)
72. Pang X. 2011 Pandemic (H1N1) 2009 among quarantined close contacts, Beijing, People's Republic of China. Emerg. Infect. Dis. 17, 1824-1830. (doi:10.3201/eid1710.101344)
73. Price GR. 1970 Selection and covariance. Nature 227, 520-521. (doi:10.1038/227520a0)
74. Price GR. 1972 Extension of covariance selection mathematics. Ann. Hum. Genet. Lond. 35, 485-490. (doi:10.1111/j.1469-1809.1957.tb01874.x)
75. Blower SM, Dowlatabadi H. 1994 Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int. Stat. Rev. 62, 229-243. (doi:10.2307/1403510)
76. Gandon S, Day T. 2009 Evolutionary epidemiology and the dynamics of adaptation. Evolution 63, 826-838. (doi:10.1111/j.1558-5646.2009.00609.x)
77. Hayden FG, Fritz R, Lobo MC, Ald W, Strober W, Straus SE. 1998 Local and systemic cytokine responses during experimental human influenza a virus infection. relation to symptom formation and host defense. J. Clin. Invest. 101, 643-649. (doi:10.1172/JCI1355)
78. Funk S, Gilad E, Watkins C, Jansen VAA. 2009 The spread of awareness and its impact on epidemic outbreaks. Proc. Natl Acad. Sci. USA 106, 6872. (doi:10.1073/pnas.0810762106)
79. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. 2009 Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 6, e1000085. (doi:10.1371/journal.pmed.1000085)
80. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. 2001 Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183, 523-531. (doi:10.1086/318537)